These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7860233)

  • 1. Phase II evaluation of merbarone in renal cell carcinoma.
    Flanigan RC; Saiers JH; Wolf M; Kraut EH; Smith AY; Blumenstein B; Crawford ED
    Invest New Drugs; 1994; 12(2):147-9. PubMed ID: 7860233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of merbarone (NSC 336628) in disseminated malignant melanoma. A Southwest Oncology Group study.
    Slavik M; Liu PY; Kraut EH; Natale RB; Flaherty LE; Sondak VK
    Invest New Drugs; 1995; 13(2):143-7. PubMed ID: 8617577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of merbarone in pancreatic carcinoma. A Southwest Oncology Group study.
    Kraut EH; Fleming T; Macdonald JS; Spiridonidis CH; Bradof JE; Baker LH
    Am J Clin Oncol; 1993 Aug; 16(4):327-8. PubMed ID: 8328410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of merbarone in soft tissue sarcoma. A Southwest Oncology Group study.
    Kraut EH; Bendetti J; Balcerzak SP; Doroshow JH
    Invest New Drugs; 1992 Nov; 10(4):347-9. PubMed ID: 1487411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II evaluation of piroxantrone in renal cell carcinoma. A Southwest Oncology Group Study.
    Allen A; Wolf M; Crawford ED; Davis MP; Natale RB; Barnett ML
    Invest New Drugs; 1992 Jul; 10(2):129-32. PubMed ID: 1500267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: The Eastern Cooperative Oncology Group Results.
    Chang AY; Kim K; Glick J; Anderson T; Karp D; Johnson D
    J Natl Cancer Inst; 1993 Mar; 85(5):388-94. PubMed ID: 8094467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
    Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatoma/merbarone. A Southwest Oncology Group study.
    Poplin EA; Tangen CM; Harvey WH; Macdonald JS
    Invest New Drugs; 1994; 12(4):337-40. PubMed ID: 7775137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of merbarone in patients with adenocarcinoma of the pancreas.
    Jones DV; Ajani JA; Winn RJ; Daugherty KR; Levin B; Krakoff IH
    Cancer Invest; 1993; 11(6):667-9. PubMed ID: 8221199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
    Look KY; Blessing JA; Adelson MD; Morris M; Bookman MA
    Am J Clin Oncol; 1996 Feb; 19(1):7-9. PubMed ID: 8554040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
    Stephens RL; Goodman P; Crawford ED; Spicer CF; Lowe BA; Ahmann FR; Chapman R; Natale RB
    Invest New Drugs; 1990; 8 Suppl 1():S69-71. PubMed ID: 2143177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
    Van Veldhuizen PJ; Faulkner JR; Lara PN; Gumerlock PH; Goodwin JW; Dakhil SR; Gross HM; Flanigan RC; Crawford ED;
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):39-45. PubMed ID: 15791454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma.
    Ajani JA; Winn R; Baez L; Pollock T; Maher T; Hallinan-Fueger B; Newman J
    Cancer Invest; 1994; 12(5):488-90. PubMed ID: 7922705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of troxacitabine (BCH-4556) in patients with advanced and/or metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
    Townsley CA; Chi K; Ernst DS; Belanger K; Tannock I; Bjarnason GA; Stewart D; Goel R; Ruether JD; Siu LL; Jolivet J; McIntosh L; Seymour L; Moore MJ;
    J Clin Oncol; 2003 Apr; 21(8):1524-9. PubMed ID: 12697876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of merbarone in patients with malignant brain tumors.
    Malik UR; Dutcher JP; Caliendo G; Lasala P; Mitnick R; Wiernik PH
    Med Oncol; 1997; 14(3-4):159-62. PubMed ID: 9468039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
    Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
    Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.
    Motzer RJ; Amato R; Todd M; Hwu WJ; Cohen R; Baselga J; Muss H; Cooper M; Yu R; Ginsberg MS; Needle M
    Invest New Drugs; 2003 Feb; 21(1):99-101. PubMed ID: 12795534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II evaluation of amonafide in renal cell carcinoma. A Southwest Oncology Group study.
    Higano CS; Goodman P; Craig JB; Kish JA; Rivkin SE; Wolf M; Crawford ED
    Invest New Drugs; 1991 Nov; 9(4):361-3. PubMed ID: 1804814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study.
    Kish JA; Wolf M; Crawford ED; Leimert JT; Bueschen A; Neefe JR; Flanigan RC
    Cancer; 1994 Aug; 74(3):916-9. PubMed ID: 8039119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
    Soori GS; Schulof RS; Stark JJ; Wiemann MC; Honeycutt PJ; Church CK; DePriest CB
    Cancer Invest; 1999; 17(6):379-84. PubMed ID: 10434947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.